Beauty Health’s latest price target has been revised downward, with the fair value estimate trimmed from $2.17 to $1.93 as analysts adopt a more conservative outlook. This adjustment comes along with a higher discount rate, rising from 10.69% to 12.24%, in response to increased perceived risk in the company’s future cash flows. For those interested in tracking how shifting analyst perspectives may impact the company moving forward, stay tuned for insights on keeping up with future updates to the Beauty Health narrative.
Stay updated as the Fair Value for Beauty Health shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Beauty Health.
Analyst sentiment toward Beauty Health remains mixed, reflecting differing perspectives on execution and future growth versus ongoing risks. The following sections summarize the key bullish and bearish takeaways from recent analyst commentary.
🐂 Bullish Takeaways
TD Cowen’s Oliver Chen has raised the firm’s price target on Beauty Health to $2.50 from $2, noting improving confidence in the company’s outlook.
Chen commends recent management actions. He emphasizes the CEO’s reset as successfully addressing device sales churn and fostering innovation in the consumables segment, which represents a substantial portion of revenues.
Deeper engagement with Beauty Health’s extensive installed provider base was viewed positively as a driver for sustained growth momentum.
🐻 Bearish Takeaways
Despite the price target increase, TD Cowen continues to maintain a Hold rating. The firm underscores reservations about nearer-term upside and the need for further proof of consistent execution.
Valuation concerns remain, with some risks perceived in the company’s ability to fully capture the anticipated benefits from its recent strategic changes.
Overall, analyst commentary from TD Cowen suggests cautious optimism. While progress under new leadership and innovation initiatives are rewarded, questions about valuation and tangible improvement remain central to Wall Street’s evolving view of Beauty Health’s stock.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
NasdaqCM:SKIN Earnings & Revenue History as at Nov 2025
The Beauty Health Company has released financial guidance for 2025, projecting net sales between $293 million and $300 million as part of its forward-looking business strategy.
Pedro Malha has been named Chief Executive Officer, with his term beginning on October 1, 2025. He will take over leadership from Marla Beck, who will move into an advisory position.
Marla Beck, the outgoing CEO, is credited with leading the company through significant operational and strategic changes that have strengthened the innovation pipeline and improved profitability.